Loading...

Therapy with JAK2 inhibitors for Myeloproliferative Neoplasms

The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs). It is now known that mutations activating the JAK-STAT pathway are ubiquitous in Ph-negative MPNs, and...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hematol Oncol Clin North Am
Main Authors: Santos, Fabio P. S., Verstovsek, Srdan
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4406395/
https://ncbi.nlm.nih.gov/pubmed/23009939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2012.07.008
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!